While there is limited research in the field regarding the various dimensions of co-use of alcohol and opioid medication, particularly related to co-use and levels of severity, our research has shown 20% to 30% of community pharmacy patients receiving opioid pain medications are engaged in co-use. Co-use of alcohol and opioid medications is a significant risk factor for opioid-related overdose. Community pharmacy is a valuable yet underutilized resource and setting for addressing the US opioid epidemic, with an untapped potential for identification of and intervention for risks associated with co-use of alcohol and opioids. This commentary describing the “Co-use of Opioid Medications and Alcohol Prevention Study (COAPS)” offers an innovative and promising approach to mitigating serious risks associated with co-use of alcohol (risk and non-risk use) and opioids in community pharmacy. COAPS aim 1involves adapting an existing opioid misuse intervention to target co-use of alcohol and opioid mediations. COAPS aim 2 involves testing the adapted intervention within a small-scale pilot randomized controlled trial (N = 40) to examine feasibility, acceptability and preliminary efficacy of the intervention versus standard care. COAPS aim 3 involves conducting key informant interviews related to future implementation of larger scale studies or service delivery in community pharmacy settings.
Common Wealth Fund. Overdose Deaths Declined But Remained Near Record Levels During the First Nine Months of 2022 as States Cope With Synthetic Opioids. Common Wealth Fund; 2023.
CowenMSLawrenceAJ.The role of opioid-dopamine interactions in the induction and maintenance of ethanol consumption. Prog Neuropsychopharmacol Biol Psychiatry. 1999;23(7):1171-1212.
7.
McCabeSEWestBTTeterCJBoydCJ.Co-ingestion of prescription opioids and other drugs among high school seniors: results from a national study. Drug Alcohol Depend. 2012;126(1-2):65-70.
8.
BrandsBBlakeJMarshDCSprouleBJeyapalanRLiS.The impact of benzodiazepine use on methadone maintenance treatment outcomes. J Addict Dis. 2008;27(3):37-48.
9.
KuerbisASaccoPBlazerDGMooreAA.Substance abuse among older adults. Clin Geriatr Med. 2014;30(3):629-654.
10.
FDA. Highlights of Prescribing Information: Oxycodone. US Food and Drug Administration; 2018.
11.
FDA. Highlights of Prescribing Information: Percocet. US Food and Drug Administration; 2018.
12.
FDA. Highlights of Prescribing Information: Oxycontin. US Food and Drug Administration; 2018.
13.
ThomasSACurayCMKiyatkinEA.Effects of alcohol on brain oxygenation and brain hypoxia induced by intravenous heroin. Neuropharmacol. 2021;197:108713.
CochranGGordonAJLo-CiganicWH, et al. An examination of claims-based predictors of overdose from a large medicaid program. Med Care. 2017;55:291-298.
16.
FDA. FDA Warns About Serious Risks and Death When Combining Opioid Pain or Cough Medicines With Benzodiazepines; Requires Its Strongest Warning. Food and Drug Administration; 2016.
17.
CDC. Alcohol Screening and Brief Intervention for People Who Consume Alcohol and Use Opioids. Centers for Disease Control and Prevention; 2018.
18.
HartzlerBDonovanDMHuangZ.Comparison of opiate-primary treatment seekers with and without alcohol use disorder. J Subst Abuse Treat. 2010;39(2):114-123.
19.
HserY-IMooneyLJSaxonAJMiottoKBellDSHuangD.Chronic pain among patients with opioid use disorder: results from electronic health records data. J Subst Abuse Treat. 2017;77:26-30.
20.
PriceAMIlgenMABohnertASB. Prevalence and correlates of nonmedical use of prescription opioids in patients seen in a residential drug and alcohol treatment program. J Subst Abuse Treat. 2011;41(2):208-214.
21.
EsserMBGuyGpJrZhangKBrewerRD.Binge drinking and prescription opioid misuse in the U.S., 2012-2014. Am J Prev Med. 2019;57(2):197-208.
22.
CochranGChenQFieldC, et al. A community pharmacy-led intervention for opioid medication misuse: A small-scale randomized clinical trial. Drug Alcohol Depend. 2019;205:107570.
23.
CochranGBacciJLYliojaT, et al. Prescription opioid use: patient characteristics and misuse in community pharmacy. JAPhA. 2016;56:248-256.e6.
24.
McNeelyJWuLTSubramaniamG, et al. Performance of the tobacco, alcohol, prescription medication, and other substance use (TAPS) tool for substance use screening in primary care patients. Ann Intern Med. 2016;165(10):690-699.
25.
SAMHSA. Key Substance Use and Mental Health Indicators in the United States: Results From the 2019 National Survey on Drug Use and Health (HHS Publication No. SMA 18-5068, NSDUH Series H-53). Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality; 2020.
26.
ReithTP.Burnout in United States healthcare professionals: a narrative review. Cureus. 2018;10(12):e3681.
27.
Accreditation Council for Pharmacy Education. Accreditation Standards and Key Elements for the Professional Program in Pharmacy Leading to the Doctor of Pharmacy Degree. Accreditation Council for Pharmacy Education; 2015.
28.
CDC. Pharmacist-Provided Medication Therapy Management in Medicaid. Centers for Disease Control and Prevention; 2021.
29.
KiniVHoPM.Interventions to improve medication adherence: a review. JAMA. 2018;320(23):2461-2473.
30.
PresleyBGrootWPavlovaM.Pharmacy-led interventions to improve medication adherence among adults with diabetes: A systematic review and meta-analysis. RSAP. 2019;15(9):1057-1067.
31.
NewmanTVSan-Juan-RodriguezAParekhN, et al. Impact of community pharmacist-led interventions in chronic disease management on clinical, utilization, and economic outcomes: an umbrella review. RSAP. 2020;16(9):1155-1165.
InciardiJASurrattHLKurtzSPCiceroTJ.Mechanisms of prescription drug diversion among drug-involved club- and street-based populations. Pain Med. 2007;8(2):171-183.
34.
CiceroTJKurtzSPSurrattHL, et al. Multiple determinants of specific modes of prescription opioid diversion. J Drug Issues. 2011;41(2):283-304.
35.
CDC. Select Features of State Pharmacist Collaborative Practice Laws. US Department of Health and Human Services, Centers for Disease Control and Prevention; 2013.
36.
DhitalRWhittleseaCMNormanIJMilliganP.Community pharmacy service users’ views and perceptions of alcohol screening and brief intervention. Drug Alcohol Rev. 2010;29(6):596-602.
37.
RiffkinR. Americans rate nurses highest on honesty, ethical standards. Gallup. Published 2014. Accessed May 17, 2016. http://www.webcitation.org/6hZbvKPDQ
38.
PeacockGKiddRRahmanA.Patient care services in independent community pharmacies: a descriptive report. JAPhA. 2007;47(6):762-767.
39.
GrabensteinJD.Essential services: quantifying the contributions of America’s pharmacists in COVID-19 clinical interventions. JAPhA. 2022;62(6):1929-1945.e1.
40.
OderdaGMLakeJRüdellKRolandCLMastersET.Economic Burden of prescription opioid misuse and abuse: A Systematic Review. J Pain Palliat Care Pharmacother. 2015;29(4):388-400.
41.
CochranGGordonAJFieldC, et al. Developing a framework of care for opioid medication misuse in community pharmacy. RSAP. 2016;12(2):293-301.
42.
CochranGRubinsteinJBacciJLYliojaTTarterR.Screening community pharmacy patients for risk of prescription opioid misuse. J Addict Med. 2015;9(5):411-416.
43.
PlattLMelendez-TorresGJO’DonnellA, et al. How effective are brief interventions in reducing alcohol consumption: do the setting, practitioner group and content matter? Findings from a systematic review and metaregression analysis. BMJ Open. 2016;6(8):e011473.
44.
PoikolainenK.Effectiveness of brief interventions to reduce alcohol intake in primary health care populations: a meta-analysis. Prev med. 1999;28(5):503-509.
45.
GhoshASinghPDasNPanditPMDasSSarkarS.Efficacy of brief intervention for harmful and hazardous alcohol use: a systematic review and meta-analysis of studies from low middle-income countries. Addiction. 2022;117(3):545-558.
46.
SchmidtCSSchulteBSeoHN, et al. Meta-analysis on the effectiveness of alcohol screening with brief interventions for patients in emergency care settings. Addiction. 2016;111(5):783-794.
47.
WingoodGMDiClementeRJ.The ADAPT-ITT Model: a novel method of adapting evidence-based HIV interventions. JAIDS. 2008;47(Suppl 1):S40-S46.
48.
MoonJKolarCBrummelAEkstrandMHoltanHRehrauerD.Development and validation of a patient satisfaction survey for comprehensive medication management. J Manag Care Spec Pharm. 2016;22(1):81-86.
49.
ThayaparanAJMahdiE.The patient satisfaction questionnaire short form (PSQ-18) as an adaptable, reliable, and validated tool for use in various settings. Med Educ Online. 2013;18:1-2. doi:10.3402/meo.v18i0.21747
50.
SobellMBSobellLCBogardisJLeoGISkinnerW.Problem drinkers’ perceptions of whether treatment goals should be self-selected or therapist-selected. Behav Ther. 1992;23:43-52.
51.
SobellLSobellM. Timeline follow-back: a technique for assessing self-reported alcohol consumption. In: LittenRZAllenJP (eds) Measuring Alcohol Consumption: Psychosocial and Biological Methods. Humana Press; 1992; 41-72.
52.
BushKKivlahanDRMcDonellMBFihnSDBradleyKA.The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). alcohol Use Disorders Identification Test. Arch Intern Med. 1998;158(16):1789-1795.
53.
DamschroderLJAronDCKeithREKirshSRAlexanderJALoweryJC.Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implement Sci. 2009;4:50.
54.
CFIR.org.The consolidated framework for implementation research. Published 2020. Accessed January 9, 2020. https://cfirguide.org/
55.
HelfrichCDLiYFSharpNDSalesAE.Organizational readiness to change assessment (Orca): development of an instrument based on the promoting action on research in Health Services (PARIHS) framework. Implement Sci. 2009;4:38.
56.
CrouchMMcKenzieH.The logic of small samples in interview-based qualitative research. Soc Sci Inf. 2006;45(4):483-499.
57.
GuestGBunceAJohnsonL.How many interviews are enough?:An experiment with data saturation and variability. Field Methods. 2006;18(1):59-82.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
